Background
==========

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) is a ubiquitous environmental contaminant that elicits a broad spectrum of biochemical and physiological effects in a species-specific manner \[[@B1]\]. These effects include lethality, cancer, developmental abnormalities, immunotoxicity, skin lesions, hepatotoxicity, and xenobiotic enzyme metabolism induction. They result from altered gene expression mediated by the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor \[[@B1],[@B2]\]. Briefly, TCDD binds to the cytoplasmic AhR causing nuclear translocation and heterodimerization with the AhR nuclear translocator (ARNT). The heterodimer then binds to specific DNA elements, termed dioxin response elements (DREs), within the regulatory regions of targeted genes to modulate expression, resulting in downstream physiological responses \[[@B3]\]. Although the structure and function of the AhR are highly conserved \[[@B4]\], the sensitivity to and the responses elicited by TCDD vary widely across species, suggesting TCDD and related compounds may activate species-specific AhR-mediated gene expression networks.

Risk assessment assumes that there is a conserved mode of action and comparable toxic responses between species. However, there are inherent differences between species that compromise the extrapolation of rodent data to estimate potential human risks. Moreover, there is a discord between preclinical animal testing compared to human clinical trials regarding toxicity \[[@B5]\]. Similarly, species differ widely in response to TCDD exposure. For example, LD~50~values range from 1 μg/kg in the guinea pig \[[@B6]\] to \>1000 μg/kg for the hamster, and several responses exhibit species-specific sensitivities and toxicities. These differential effects are not attributed to differences in binding affinity or AhR complex stability \[[@B7]-[@B9]\]. Collectively, these data suggest that although the AhR is well conserved, subsequent differential gene expression responses are species-specific.

To further investigate differences in TCDD elicited differential gene expression, global gene expression was assessed in human HepG2, mouse Hepa1c1c7 and rat H4IIE hepatoma cells following treatment with TCDD. Comparative analysis indicates there are significant differences in gene expression between species, suggesting AhR-mediated gene expression may not be conserved.

Results
=======

Temporally Conserved Gene Expression Responses Elicited by TCDD
---------------------------------------------------------------

Species-specific, cDNA microarrays were used to profile the temporal gene expression elicited by TCDD in human HepG2, mouse Hepa1c1c7 and rat H4IIE cells. The microarrays queried 6995, 8478 and 5169 unique human, mouse and rat genes, respectively (Table [1](#T1){ref-type="table"}). Empirical Bayes analysis identified 691, 439 and 57 differentially expressed genes (P1(t) \> 0.999 and \|fold change\| \> 1.4) in HepG2, Hepa1c1c7 and H4IIE cells, respectively. Complete cDNA microarray data sets are provided in Additional files [1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}. HepG2 cells were the most responsive as indicated by both the overall number of differentially expressed genes as well as the number of responsive genes at each time point (Figure [1](#F1){ref-type="fig"}). H4IIE cells exhibited significantly less differentially expressed genes, partially explained by the smaller microarray and the immaturity of rat genome annotation compared to the human and mouse. Differentially expressed genes were hierarchically clustered based on Euclidian distance and distinct clusters of temporal gene expression patterns were identified (Figure [2](#F2){ref-type="fig"}).

###### 

Gene coverage of species-specific cDNA microarray platforms and number of differentially regulated genes

                    Human HepG2   Mouse Hepa1c1c7   Rat H4IIE                 
  ----------------- ------------- ----------------- ----------- ----- ------- ----
  Unique Genes^b^   6,995         624               8,478       438   5,169   56
  Orthologs^c^      6,825         616               8,233       432   4,871   52

^a^\|fold change\| \> 1.4 and P1(t) \> 0.999

^b^based on Entrez GeneID

^c^based on HomoloGeneID

![**Number of TCDD-elicited differentially expressed genes in human HepG2, mouse Hepa1c1c7 and rat H4IIE**. Global gene expression changes were detected using cDNA microarray analysis of cells treated with 10 nM TCDD for 1, 2, 4, 8, 12, 24 and 48 hrs. Differentially expressed genes are defined as having P1(t) \> 0.999 and \|fold change\| \> 1.4-fold at one or more time points.](1471-2164-12-193-1){#F1}

![**Hierarchical clustering of differentially expressed genes (P1(t) \> 0.999 and \|fold change\| \> 1.4) from cDNA microarray time course studies in HepG2, Hepa1c1c7 and H4IIE hepatoma cells**.](1471-2164-12-193-2){#F2}

Pair-wise comparisons of differentially expressed genes were conducted using HomoloGene (build 35) defined orthologs (Figure [3A](#F3){ref-type="fig"}). Human and mouse cDNA microarrays shared 4546 orthologous genes, however only 0.9% (41 orthologs; Additional file [4](#S4){ref-type="supplementary-material"}) were differentially regulated by TCDD in HepG2 and Hepa1c1c7 cells. Comparison of the rodent platforms identified 3850 orthologs with only 0.2% (8 orthologs; Additional file [5](#S5){ref-type="supplementary-material"}) responding in both Hepa1c1c7 and H4IIE cells. The lack of conserved ortholog differential expression in Hepa1c1c7 and H4IIE cells is consistent with the reported differences in differential expression observed *in vivo*between mice and rats \[[@B10]-[@B12]\]. Time dependent profiling of HepG2 and H4IIE gene expression identified only 5 conserved responses out of 2625 possible orthologs, representing only 0.2% (Additional file [6](#S6){ref-type="supplementary-material"}). Comparative analysis across all three species with 2252 shared orthologous probes identified only one ortholog that was differentially regulated in all three cell lines (immediate early response 3, IER3; HomoloGene ID 2894). Note that other members of the AhR gene battery, namely CYP1A1, ALDH3A1 and NQO1, were not present across all of the cDNA microarray platforms. However, their responses were also conserved across all three cell lines when measured using QRTPCR. The results for CYP1A1 are shown in Figure [4](#F4){ref-type="fig"}.

![**Cross-species comparison of TCDD-elicited temporal gene expression responses using cDNA microarrays**. (A) The lower half (dark boxes) of the matrix show the number of orthologs represented between pairs of species-specific cDNA microarray platforms. The upper half (grey boxes) of the matrix provides the number of TCDD elicited differentially expressed orthologs between pairs of cell lines. (B) The Venn diagram shows the overlap of all differentially expressed genes (P1(t) \> 0.999 and \|fold change\| \> 1.4) from 2,252 possible orthologs represent across all three microarray platforms. Additional files [4](#S4){ref-type="supplementary-material"}, [5](#S5){ref-type="supplementary-material"}, [6](#S6){ref-type="supplementary-material"} lists the shared responses between pairs of species.](1471-2164-12-193-3){#F3}

![**QRTPCR verification of the conserved induction of CYP1A1 across the human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines**. The same RNA used for microarray analysis was examined by QRTPCR. Fold changes were calculated relative to time-matched vehicle controls. Error bars represent the standard error of measurement for the average fold change and the asterisk (\*) indicates p \< 0.05.](1471-2164-12-193-4){#F4}

Identification of Putative Primary Gene Expression Responses
------------------------------------------------------------

In order to further investigate AhR-mediated responses, TCDD-elicited differential gene expression was examined in the presence of cycloheximide (CHX), a protein translation inhibitor. Putative primary responses were defined in this study as those where CHX co-treatment either maintained or enhanced the response elicited by TCDD, while responses that were attenuated or blocked by CHX co-treatment were classified as secondary responses based on their assumed dependence on additional protein translation. cDNA microarray analysis confirmed the superinduction of CYP1A1 mRNA in CHX co-treated Hepa1c1c7 cells \[[@B13],[@B14]\], consistent with the superinduction in human MCF10A cells treated with TCDD \[[@B15]\]. Additionally, Hepa1c1c7 ARNT-deficient c4 mutants treated with TCDD did not exhibit induction of the prototypical AhR battery genes including CYP1A1 \[[@B16]\]. Collectively, these results indicate that CYP1A1 is a primary gene expression response consistent with the direct interaction of the AhR with DREs within the promoter region.

For each species, differentially expressed orthologs were classified as primary or secondary responses based on CHX co-treatment studies at both 4 and 12 hrs. Overall 61, 38 and 2 human, mouse and rat orthologs, respectively, were considered primary responses (Additional files [7](#S7){ref-type="supplementary-material"}, [8](#S8){ref-type="supplementary-material"}, [9](#S9){ref-type="supplementary-material"}). Furthermore, 45, 12 and 10 orthologous genes in the HepG2, Hepa1c1c7 and H4IIE cells were classified as secondary AhR responses (Additional files [10](#S10){ref-type="supplementary-material"}, [11](#S11){ref-type="supplementary-material"}, [12](#S12){ref-type="supplementary-material"}). Comparative examination of the CHX co-treatment data suggested that each cell line had its own unique set of primary responsive orthologs.

Whole-Genome Analysis of Conserved TCDD-Elicited Gene Expression Responses
--------------------------------------------------------------------------

The lack of whole genome coverage on the human, mouse and rat cDNA microarrays limited the number of orthologs that could be investigated. Therefore, whole genome expression analysis was performed at 24 hrs, one of the most active time points in terms of the number of differentially expressed genes (Figure [1](#F1){ref-type="fig"}), using 4 × 44 k Agilent oligonucleotide microarrays. Each microarray contained more than 41,000 individual probes, representing more than 18,000 unique genes (Table [2](#T2){ref-type="table"}). Despite the increased coverage, the number of TCDD elicited differentially expressed genes were surprisingly small relative to the cDNA microarray results. For example, the human Agilent microarray consisted of 19,406 known genes, representing a 2.8-fold increase in coverage compared to the human cDNA microarray. However, only 899 unique genes were differentially expressed, a modest increase from the 691 genes identified using cDNA microarrays. Similarly, only 519 and 121 genes were responsive in the Hepa1c1c7 and H4IIE cells, respectively. Complete Agilent microarray data sets are provided in Additional files [13](#S13){ref-type="supplementary-material"}, [14](#S14){ref-type="supplementary-material"}, [15](#S15){ref-type="supplementary-material"}.

###### 

Gene coverage of species-specific Agilent microarray platforms and number of differentially regulated genes

                    Human HepG2   Mouse Hepa1c1c7   Rat H4IIE                  
  ----------------- ------------- ----------------- ----------- ----- -------- -----
  Unique Genes^b^   18,499        865               20,929      508   18,244   129
  Orthologs^c^      16,781        828               17,543      477   15,705   116

^a^\|fold change\| \> 1.4 and P1(t) \> 0.999

^b^based on Entrez GeneID

^c^based on HomoloGeneID

The use of whole genome microarrays also increased the number of orthologs that could be examined (Figure [5A](#F5){ref-type="fig"}). As seen with the cDNA microarray dataset pair-wise comparisons, HepG2 and Hepa1c1c7 cells shared the greatest number of TCDD responsive orthologs (Additional files [16](#S16){ref-type="supplementary-material"}, [17](#S17){ref-type="supplementary-material"}, [18](#S18){ref-type="supplementary-material"}). Ortholog coverage between all three species increased from 2252 on the cDNA microarrays to 12,388 across the Agilent platforms. Comparative analysis (P1(t) \> 0.999 and \|fold change\| \> 1.4) identified only 10 orthologs that were differentially expressed by TCDD at 24 hrs (Figure [5B](#F5){ref-type="fig"}; Table [3](#T3){ref-type="table"}). Whole genome expression profiling identified the species-conserved induction of CYP1A1, TIPARP and UGT1A6 in all three cell lines. Despite this increased coverage, the number of differentially expressed orthologs across all three cell lines remained small, consistent with our cDNA microarray results.

![**Cross-species comparison of TCDD-elicited gene expression responses at 24 hrs using 4 × 44 k Agilent microarrays**. (A) The lower half (dark boxes) of the matrix show the number or orthologous genes represented between pairs of species-specific microarrays. The upper half (grey boxes) provides the number of TCDD-elicited differentially expressed orthologs between pairs of cell lines. (B) The 3-way Venn diagram shows the overlap of all differentially expressed genes (P1(t) \> 0.999 and \|fold change\| \> 1.4) from 12,388 possible orthologous genes represented across all three platforms. The 9 genes differentially expressed in all three cell lines are listed in Table 3. Additional files [16](#S16){ref-type="supplementary-material"}, [17](#S17){ref-type="supplementary-material"}, [18](#S18){ref-type="supplementary-material"} lists the shared responses between pairs of species.](1471-2164-12-193-5){#F5}

###### 

List of common genes identified as differentially expressed by TCDD treatment from whole genome Agilent microarray analysis.

  Gene Symbol   Gene Name                                                                Homologene ID   Fold change^a^                             
  ------------- ------------------------------------------------------------------------ --------------- ---------------- --- -------- --- -------- ---
  NQO1          NAD(P)H dehydrogenase, quinone 1                                         695             3.22             ▲   4.88     ▲   4.82     ▲
  CCND1         cyclin D1                                                                1334            1.57             ▲   -1.56    ▼   -1.47    ▼
  ID3           inhibitor of DNA binding 3, dominant negative helix-loop-helix protein   1633            1.74             ▲   -1.83    ▼   -1.68    ▼
  TIPARP        TCDD-inducible poly(ADP-ribose) polymerase                               9167            1.47             ▲   7.05     ▲   2.91     ▲
  POC1A         POC1 centriolar protein homolog A                                        51460           -1.64            ▼   -1.67    ▼   -1.57    ▼
  CYP1A1        cytochrome P450, family 1, subfamily A, polypeptide 1                    68062           13.64            ▲   153.52   ▲   134.16   ▲
  GSTA5         glutathione S-transferase A5                                             74378           -2.47            ▼   1.47     ▲   5.85     ▲
  UGT1A6        UDP glucuronosyltransferase 1 family, polypeptide A6                     85959           2.09             ▲   2.24     ▲   2.06     ▲
  MT1E          metallothionein 1E                                                       108228          4.89             ▲   -1.66    ▼   2.65     ▲

*^a^*Maximum absolute foldchange determined by microarray analysis

*^b^*Differentially regulated genes with P1(t) \> 0.999 and \|foldchange\| \> 1.4

Species-Specific & Species-Divergent Gene Expression Responses
--------------------------------------------------------------

Whole genome comparative analysis of HepG2, Hepa1c1c7 and H4IIE responses identified genes that were species-specific, i.e. differentially expressed in only a single species. For example, microarray analysis at 24 hrs found that fibromodulin (FMOD, HomoloGene ID 1530) was significantly up-regulated 17.2-fold in the HepG2 cells while no significant change in expression was detected in the Hepa1c1c7 and H4IIE cells. Other examples of mouse and rat specific responses include forkhead box Q1 (FOXQ1, HomoloGene ID 7359) and ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2, HomoloGene ID 20333). FOXQ1 was up-regulated 5.9-fold in the Hepa1c1c7 cells while ENTPD2 was up-regulated 3.2-fold in the H4IIE cells. For both of these genes, the corresponding ortholog in the other two species did not exhibit significant differential expression. The species-specific responses of FMOD, FOXQ1 and ENTPD were verified using QRTPCR (Figure [6](#F6){ref-type="fig"}). These responses are consistent with previous reports of species-specific TCDD elicited hepatic gene expression characterized in mice and rats \[[@B10],[@B11]\].

![**QRTPCR verification of examples of species-specific orthologous gene expression responses identified from whole-genome microarray analysis at 24 hrs in the human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines**. The same RNA used for microarray analysis was examined by QRTPCR. Representative orthologs that exhibited significant expression in only one species were verified; FMOD, ENTPD2 and FOXQ1 and were differentially expressed in only the HepG2, Hepa1c1c7 and H4IIE cells respectively. Fold changes were calculated relative to time-matched vehicle controls. Error bars represent the standard error of measurement for the average fold change and the asterisk (\*) indicates p \< 0.05.](1471-2164-12-193-6){#F6}

Comparative analysis of the orthologous gene expression responses in HepG2, Hepa1c1c7 and H4IIE datasets identified 10 orthologs that were differentially expressed by TCDD across the three models. Further analysis indicated that not all of these responses were directionally conserved, i.e. pattern of expression was not the same in all species. For example, IER3 was induced 1.4-fold in Hepa1c1c7 cells at 4 hrs and 1.5-fold in H4IIE cells at 12 hrs, but repressed -1.9-fold in HepG2 cells at 24 hrs. Likewise, glutathione S-transferase alpha 5 (GSTA5, HomoloGene ID 74378) was induced 1.5-fold in Hepa1c1c7 cells and 4.9-fold in H4IIE cells, but down-regulated 2.5-fold in HepG2 cells. QRTPCR confirmed the divergent expression of GSTA5 in the rat and human cell lines, but found Hepa1c1c7 cells were relatively non-responsive (Figure [7A](#F7){ref-type="fig"}). Two other orthologs, cyclin D1 (CCND, HomoloGene ID 1334) and inhibitor of DNA binding 3 (ID3, HomoloGene ID 1633), also exhibited divergent expression between species, where the orthologs were down-regulated in the rodent cell lines but induced in HepG2 cells (Table [3](#T3){ref-type="table"}). Species-specific and species-divergent responses have also been reported *in vivo*for TCDD elicited hepatic differential gene expression in mice and rats \[[@B10],[@B11]\].

![**Comparative analysis of GSTA5 orthologs**. (A) QRTPCR verification of the divergent expression of GSTA5 orthologs in human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines. Fold changes were calculated relative to time-matched vehicle controls. Error bars represent the standard error of measurement for the average fold change and the asterisk (\*) indicates p \< 0.05. (B) Gene regulatory regions (-10,000 to 1,000 bp relative to the transcription start site \[TSS\]) were computationally searched for the 5 bp DRE core (GCGTC) and indicated by the grey boxes. Each core was extended by the flanking 7 bp, and the resulting 19 bp sequence (C) was compared to a consensus DRE sequence using a position weight matrix developed from *bona fide*functional DREs. The shaded rows in (C) indicate the highly similar mouse and rat DRE sequences (Euclidean ≤ 3.0).](1471-2164-12-193-7){#F7}

Functional Enrichment and Network Analysis
------------------------------------------

Microarray analysis identified a small subset of TCDD responsive genes in the entire genome of each species. Differentially expressed genes elicited by TCDD in each cell line were clustered for functional enrichment based on GO terms (enrichment score ≥ 1.5). Enriched HepG2, Hepa1c1c7, and H4IIE responses clusters included GO terms related to xenobiotic exposure (GO:0009410) and metabolism (GO:0006805) (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}), indicating that these processes are conserved in all three cell lines, and consistent with reported *in vivo*studies using rats and mice\[[@B10]-[@B12]\]. However, other enriched GO terms, such as those related to lipid metabolism and transport, were only enriched in HepG2 and H4IIE cell lines. Genes functionally related to lipid metabolism were further analyzed using Ingenuity Pathway Analysis to identify a network of TCDD-responsive orthologs, and species-conserved and -specific responses (Figure [8](#F8){ref-type="fig"}). Although GO terms related to lipid metabolism were enriched HepG2 and H4IIE differential gene expression data sets, there were few orthologs that exhibited differential regulation in both cell lines based on the fold-change and statistical cutoffs used. *In vivo*rat studies also identified enrichment of genes related to lipid metabolism following TCDD treatment, suggesting that H4IIE cells may be predictive of TCDD-induced perturbations of this pathway rats.

###### 

Functional enrichment analysis of differentially regulated^a^genes elicited by TCDD in HepG2 cells using DAVID.

  Category                     Term                                                                 Gene count   Fold enrichment   P-value
  ---------------------------- -------------------------------------------------------------------- ------------ ----------------- ----------
  **Enrichment Score: 2.99**                                                                                                       
   GOTERM_BP_3                 GO:0009410 \~ response to xenobiotic stimulus                        10           8.03              1.54E-06
   GOTERM_BP_3                 GO:0006805 \~ xenobiotic metabolic process                           9            8.32              4.92E-06
   GOTERM_BP_3                 GO:0017144 \~ drug metabolic process                                 3            3.46              2.13E-01
   GOTERM_BP_3                 GO:0006800 \~ oxygen and reactive oxygen species metabolic process   4            1.12              7.00E-01
                                                                                                                                   
  **Enrichment Score: 2.71**                                                                                                       
   GOTERM_BP_3                 GO:0022403 \~ cell cycle phase                                       40           1.80              4.36E-04
   GOTERM_BP_3                 GO:0048285 \~ organelle fission                                      25           2.03              1.35E-03
   GOTERM_BP_3                 GO:0000278 \~ mitotic cell cycle                                     34           1.70              3.07E-03
   GOTERM_BP_3                 GO:0022402 \~ cell cycle process                                     45           1.48              8.10E-03
                                                                                                                                   
  **Enrichment Score: 2.30**                                                                                                       
   GOTERM_BP_3                 GO:0006629 \~ lipid metabolic process                                70           1.65              3.82E-05
   GOTERM_BP_3                 GO:0008610 \~ lipid biosynthetic process                             25           1.47              5.48E-02
   GOTERM_BP_3                 GO:0044255 \~ cellular lipid metabolic process                       37           1.34              6.10E-02
                                                                                                                                   
  **Enrichment Score: 2.03**                                                                                                       
   GOTERM_BP_3                 GO:0006790 \~ sulfur metabolic process                               15           2.41              3.58E-03
   GOTERM_BP_3                 GO:0006518 \~ peptide metabolic process                              9            3.20              6.37E-03
   GOTERM_BP_3                 GO:0051186 \~ cofactor metabolic process                             20           1.91              8.81E-03
   GOTERM_BP_3                 GO:0006519 \~ cellular amino acid and derivative metabolic process   28           1.48              3.94E-02
                                                                                                                                   
  **Enrichment Score: 1.63**                                                                                                       
   GOTERM_BP_3                 GO:0005975 \~ carbohydrate metabolic process                         43           1.55              4.51E-03
   GOTERM_BP_3                 GO:0044262 \~ cellular carbohydrate metabolic process                32           1.56              1.40E-02
   GOTERM_BP_3                 GO:0016051 \~ carbohydrate biosynthetic process                      12           2.09              2.79E-02
   GOTERM_BP_3                 GO:0005996 \~ monosaccharide metabolic process                       19           1.62              4.67E-02
   GOTERM_BP_3                 GO:0046165 \~ alcohol biosynthetic process                           6            2.52              8.71E-02
                                                                                                                                   
  **Enrichment Score: 1.57**                                                                                                       
   GOTERM_BP_3                 GO:0010817 \~ regulation of hormone levels                           17           2.11              6.67E-03
   GOTERM_BP_3                 GO:0034754 \~ cellular hormone metabolic process                     9            2.87              1.22E-02
   GOTERM_BP_3                 GO:0042446 \~ hormone biosynthetic process                           4            2.38              2.34E-01

*^a^*Differentially regulated genes with P1(t) \> 0.999 and \|foldchange\| \> 1.4

###### 

Functional enrichment analysis of differentially regulated^a^genes elicited by TCDD in Hepa1c1c7 cells using DAVID.

  Category                      Term                                                         Gene count   Fold enrichment   P-value
  ----------------------------- ------------------------------------------------------------ ------------ ----------------- ----------
  **Enrichment Score: 18.67**                                                                                               
   GOTERM_BP_3                  GO:0000278 \~ mitotic cell cycle                             43           5.95              7.67E-21
   GOTERM_BP_3                  GO:0022402 \~ cell cycle process                             52           4.50              1.15E-19
   GOTERM_BP_3                  GO:0022403 \~ cell cycle phase                               47           4.87              3.67E-19
   GOTERM_BP_3                  GO:0048285 \~ organelle fission                              36           6.14              6.31E-18
                                                                                                                            
  **Enrichment Score: 2.05**                                                                                                
   GOTERM_BP_3                  GO:0006805 \~ xenobiotic metabolic process                   4            11.20             4.67E-03
   GOTERM_BP_3                  GO:0009410 \~ response to xenobiotic stimulus                4            8.96              9.05E-03
   GOTERM_BP_3                  GO:0006725 \~ cellular aromatic compound metabolic process   9            2.75              1.66E-02
                                                                                                                            
  **Enrichment Score: 2.04**                                                                                                
   GOTERM_BP_3                  GO:0048522 \~ positive regulation of cellular process        58           1.51              1.41E-03
   GOTERM_BP_3                  GO:0042127 \~ regulation of cell proliferation               27           1.72              7.62E-03
   GOTERM_BP_3                  GO:0008284 \~ positive regulation of cell proliferation      14           1.69              7.12E-02
                                                                                                                            
  **Enrichment Score: 1.62**                                                                                                
   GOTERM_BP_3                  GO:0051640 \~ organelle localization                         7            4.36              5.10E-03
   GOTERM_BP_3                  GO:0051651 \~ maintenance of location in cell                4            5.38              3.68E-02
   GOTERM_BP_3                  GO:0051235 \~ maintenance of location                        4            4.07              7.35E-02

*^a^*Differentially regulated genes with P1(t) \> 0.999 and \|foldchange\| \> 1.4

###### 

Functional enrichment analysis of differentially regulated^a^genes elicited by TCDD in H4IIE cells using DAVID.

  Category                     Term                                                                 Gene count   Fold enrichment   P-value
  ---------------------------- -------------------------------------------------------------------- ------------ ----------------- ----------
  **Enrichment Score: 3.05**                                                                                                       
   GOTERM_BP_3                 GO:0006805 \~ xenobiotic metabolic process                           7            34.21             3.52E-08
   GOTERM_BP_3                 GO:0009410 \~ response to xenobiotic stimulus                        7            31.47             6.09E-08
   GOTERM_BP_3                 GO:0006725 \~ cellular aromatic compound metabolic process           6            5.07              6.28E-03
   GOTERM_BP_3                 GO:0017144 \~ drug metabolic process                                 3            16.86             1.31E-02
   GOTERM_BP_3                 GO:0051186 \~ cofactor metabolic process                             6            3.61              2.44E-02
   GOTERM_BP_3                 GO:0046483 \~ heterocycle metabolic process                          5            1.78              3.03E-01
   GOTERM_BP_3                 GO:0044248 \~ cellular catabolic process                             8            1.39              3.41E-01
                                                                                                                                   
  **Enrichment Score: 2.45**                                                                                                       
   GOTERM_BP_3                 GO:0010035 \~ response to inorganic substance                        11           4.70              1.00E-04
   GOTERM_BP_3                 GO:0006800 \~ oxygen and reactive oxygen species metabolic process   5            10.81             1.10E-03
   GOTERM_BP_3                 GO:0006979 \~ response to oxidative stress                           7            4.50              4.38E-03
   GOTERM_BP_3                 GO:0044248 \~ cellular catabolic process                             8            1.39              3.41E-01
                                                                                                                                   
  **Enrichment Score: 1.59**                                                                                                       
   GOTERM_BP_3                 GO:0006629 \~ lipid metabolic process                                14           2.49              3.37E-03
   GOTERM_BP_3                 GO:0006082 \~ organic acid metabolic process                         12           2.71              4.12E-03
   GOTERM_BP_3                 GO:0042180 \~ cellular ketone metabolic process                      12           2.68              4.57E-03
   GOTERM_BP_3                 GO:0044255 \~ cellular lipid metabolic process                       11           2.77              5.68E-03
   GOTERM_BP_3                 GO:0005996 \~ monosaccharide metabolic process                       7            4.23              5.88E-03
   GOTERM_BP_3                 GO:0016051 \~ carbohydrate biosynthetic process                      5            6.18              8.38E-03
   GOTERM_BP_3                 GO:0044262 \~ cellular carbohydrate metabolic process                7            2.63              4.80E-02
   GOTERM_BP_3                 GO:0046165 \~ alcohol biosynthetic process                           3            8.03              5.25E-02
   GOTERM_BP_3                 GO:0005975 \~ carbohydrate metabolic process                         8            2.25              6.22E-02
   GOTERM_BP_3                 GO:0006091 \~ generation of precursor metabolites and energy         5            2.70              1.11E-01
   GOTERM_BP_3                 GO:0008610 \~ lipid biosynthetic process                             4            1.71              4.09E-01
   GOTERM_BP_3                 GO:0044249 \~ cellular biosynthetic process                          16           1.04              5.74E-01
                                                                                                                                   
  **Enrichment Score: 1.58**                                                                                                       
   GOTERM_BP_3                 GO:0042493 \~ response to drug                                       11           3.94              4.20E-04
   GOTERM_BP_3                 GO:0006869 \~ lipid transport                                        4            3.91              8.07E-02
   GOTERM_BP_3                 GO:0010876 \~ lipid localization                                     4            3.54              1.01E-01
   GOTERM_BP_3                 GO:0042592 \~ homeostatic process                                    10           1.66              1.39E-01
                                                                                                                                   
  **Enrichment Score: 1.54**                                                                                                       
   GOTERM_BP_3                 GO:0044255 \~ cellular lipid metabolic process                       11           2.77              5.68E-03
   GOTERM_BP_3                 GO:0006721 \~ terpenoid metabolic process                            3            10.54             3.20E-02
   GOTERM_BP_3                 GO:0006766 \~ vitamin metabolic process                              3            4.75              1.29E-01

*^a^*Differentially regulated genes with P1(t) \> 0.999 and \|foldchange\| \> 1.4

![**Gene interaction network of TCDD-responsive orthologs functionally related to lipid metabolism**. Molecules are represented by nodes connected by arrows to indicate either direct or indirect relationships (dotted lines). Colors in the gene expression boxes represent the direction and magnitude of the gene expression responses from the Agilent microarrays. The network visualizes species-conserved and -divergent gene expression responses elicited by TCDD in the human HepG2, mouse Hepa1c1c7 and rat H4IIE cell lines.](1471-2164-12-193-8){#F8}

Despite the nature of these continuous cell lines and the dysregulation of genes related to cell cycle control and regulation, GO terms associated with these functions were not enriched across all three cell lines. TCDD-treated Human HepG2 and mouse Hepa1c1c7 cell lines identified Functional clusters associated with cell cycle control (GO:0022402) were in enriched TCDD-treated HepG2 and Hepa1c1c7 gene expression data sets, but not in the H4IIE data set. Species-differences in functional clustering of TCDD-elicited differentially expressed gene data sets further corroborate species-specific responses to TCDD.

Dioxin Response Element Analysis
--------------------------------

Putative functional DREs are not equally distributed between species with more DREs associated with known human genes \[[@B17],[@B18]\]. Within the human genome, there are 213,355 DRE cores in the proximal promoter regions of known genes (10kb upstream to 1kb downstream of a transcriptional start site \[TSS\]), with 139,289 and 100,614 DRE cores, in the mouse and rat genomes, respectively. To further investigate the divergent expression of CCND1, ID3 and GSTA5, their proximal promoter regions were searched for DRE cores. Human orthologs of CCND1 and ID3 contained 12 and 14 DRE cores, respectively, greater than the number found in either the mouse or rat genomes. In contrast, mouse and rat orthologs of GSTA5 each had 7 and 12 DRE cores, respectively, while the human only had 3 (Figures [7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). In each of these divergently regulated orthologs, the species with the greatest number of DRE cores within the regulatory region had the highest fold induction suggesting that species-specific regulons have important roles in regulating gene expression.

Each DRE core in the GSTA5 orthologs was extended by 7 bp on either end and assessed for sequence similarity by measuring the Euclidean distance between sequence pairs. Only the mouse and rat GSTA5 contained highly similar DRE sequences (Euclidian distance of ≤ 3.0; shaded rows in Figure [7C](#F7){ref-type="fig"}), and no human DRE sequences with high sequence similarity. Furthermore, the position of the conserved DRE sequence 5 bp upstream of the TSS in the mouse appears to be positionally conserved with the DRE sequence in rat the ortholog located 22 bp upstream of the TSS. Collectively, the disproportionate number of DREs between species and lack of sequence and spatially conserved DREs may account for the divergent regulation of human, mouse and rat GSTA5 orthologs.

Discussion
==========

This study comprehensively and systematically compares the gene expression responses elicited by TCDD across human, mouse and rat cells. Incorporating both custom cDNA microarrays to profile the temporal responses and more comprehensive commercial oligonucleotide microarrays, a limited number of conserved responses between species were identified. In addition, divergent and a large number of species-specific responses were identified that may contribute to species-specific differences in sensitivity and toxicity. These results are consistent with the poor response correlations of orthologous genes between C57BL/6 mice, Sprague Dawley and Long-Evans rats \[[@B10],[@B11]\]. Collectively, reported *in vivo*rodent comparisons, and the *in vitro*data presented in this study suggest there are significant differences in TCDD elicited gene expression between species, despite the conservation of the AhR \[[@B4]\] and its signaling pathway.

*In vivo*and *in vitro*studies examining TCDD-elicited global gene expression have demonstrated that AhR targets a limited portion of the genome \[[@B10]-[@B12],[@B19]-[@B23]\]. In addition, PWM-based computational searches identified a low percentage of orthologs with conserved putative functional DREs within their regulatory regions (10kb upstream of the TSS and the 5\'UTR) \[[@B17],[@B18]\]. Our comparative *in vitro*microarray results corroborate these findings. Temporal analysis using custom cDNA microarrays found that TCDD elicited a response in 9.9% of the represented genes in the HepG2 cells, 5.2% in the Hepa1c1c7 cells and only 1.1% in the H4IIE cells. Similar results were obtained using whole-genome microarrays where 4.7%, 2.4% and 0.7% of the genes exhibiting differential expression in HepG2, Hepa1c1c7 and H4IIE cells, respectively, at 24 hrs.

All three cell lines differentially expressed a core set of conserved gene responses that included the induction of CYP1A1, NQO1 and UGT1A6, members of the AhR gene battery \[[@B24]\]. However, a significant number of responses were specific to a single species (Figures [3B](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), as reported in *in vivo*studies \[[@B10],[@B11]\]. Moreover, these studies not only identified species-specific responses, but also orthologs with divergent responses (i.e. same gene up-regulated in one species and down-regulated in other). Comparisons of C57BL/6 mouse and Sprague Dawley rat responses found that 29% of the commonly regulated orthologs exhibited divergent regulation \[[@B11]\]. Similarly, GSTA5, CCND1 and ID3, exhibited divergent regulation across HepG2, Hepa1c1c7 and H4IIE cells (Table [3](#T3){ref-type="table"}). Each of these genes exhibited the same pattern with Hepa1c1c7 and H4IIE cells having comparable profiles while HepG2 cells exhibited the divergent response. For example, GSTA5 was up-regulated in Hepa1c1c7 and H4IIE cells, but down-regulated in HepG2 cells (Table [3](#T3){ref-type="table"}). *In vivo*gene expression responses of GSTA5 orthologs matched the *in vitro*responses in the Hepa1c1c7 and H4IIE cells; TCDD treated mice and rats exhibited 1.8- and 1.9-fold maximum induction, respectively \[[@B11],[@B12]\]. QRTPCR verified the divergent response of GSTA5 in the H4IIE and HepG2 cells, but did not detect a significant induction in the Hepa1c1c7 cells (Figure [7A](#F7){ref-type="fig"}).

Computational analysis of GST5A found a disproportionate number of DRE cores within the regulatory region sequence of each species (Figure [7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). Sequence analysis also found DRE sequences with high similarity in the mouse and rat orthologs, but not in the human GSTA5. The identification of species-specific DREs is consistent with the divergent regulation of GSTA5 between these cell lines. Overall, differences in ortholog expression may contribute to differences in TCDD sensitivity and toxicity across species.

Although these continuous cells lines are similar in morphology and were derived from hepatomas, there are inherent differences that may bias the identification of species-conserved and -divergent responses. For example, HepG2 cells were originally derived from the liver biopsy of a 15-year old Caucasian male and therefore may not be representative of a mature adult liver \[[@B25]\]. Recent studies have compared basal gene expression of liver samples to primary human hepatocytes, HepG2 and HepaRG cells, another human hepatoma cell line. Although, HepaRG cells were most similar to primary hepatocytes and liver samples \[[@B26]\], toxicogenomic studies report that HepaRG and HepG2 gene expression responses retained common functional processes \[[@B27]\]. In addition, the HepaRG donor differed in age and sex compared to the HepG2 patient, and was also infected with hepatitis C, which may affect both basal and TCDD-elicited gene expression. HepG2 cells were more sensitive in terms of the magnitude of regulation, and also in the terms of the total number of differentially regulated genes, and may be a more sensitive model for assessing TCDD exposure \[[@B27]\].

Conclusion
==========

Although a core set of conserved gene responses was identified, consistent with the role of AhR in mediating the adaptive metabolic responses, further evidence of differences in genome-wide gene expression profiles between species (i.e. species-specific regulons) is also presented. This is consistent with species-specific differences in TCDD sensitivity and toxicity \[[@B6],[@B8],[@B28],[@B29]\], which are due to alterations in gene expression. Furthermore, there is a lack of conserved putative DREs within orthologous genes \[[@B18]\], and differences in genome-wide gene expression profiles has been reported between mice and rats *in vivo*\[[@B10],[@B11]\]. Undoubtedly, the number of conserved responses and immaturity of the genome annotation, especially for the rat, limits the overall interspecies comparison \[[@B30]\]. Differences in AhR levels, co-activator availability, and protocols used in their isolation of these hepatoma cells may confound our comparisons. Nevertheless, the identification of numerous species-specific responses, evidence of divergent gene expression responses between species, and the discovery of distinct putative primary response sets in each cell line provides further compelling evidence that the effects of TCDD post-AhR binding are not conserved between species.

Methods
=======

Cell Culture and Treatment
--------------------------

HepG2 (Dr. Trevor Archer, NIEHS, Research Triangle Park, NC), Hepa1c1c7 (Dr. Oliver Hankinson, University of California, Los Angeles, CA), and H4IIE (Dr. Niels Bols, University of Waterloo, Waterloo, Canada) cells were cultured in monolayers and treated with TCDD (S. Safe, Texas A&M University, College Station, TX) as previously described \[[@B16]\]. Briefly, cells were treated with either 10 nM TCDD or DMSO vehicle control for 1, 2, 4, 8, 12, 24 or 48 hrs for the time course studies. For co-treatment studies, cells were pretreated with 10 mg/ml cycloheximide (CHX; Sigma) for 1 hr and then treated for an additional 4 or 12 hrs with 10 nM TCDD or DMSO vehicle (Additional file [19](#S19){ref-type="supplementary-material"}). All treatment studies were performed in triplicate.

RNA Isolation
-------------

Cells were harvested with 2.0 mL of TRIzol® Reagent (Invitrogen) and total RNA isolated according to the manufacturer\'s protocol followed by an acid phenol:chloroform extraction. Isolated RNA was resuspended in The RNA Storage Solution (Ambion Inc., Austin, TX), quantified (A~260~), and assessed for purity by measuring the A~260~/A~280~ratio and by visual inspection of 1.0 μg on a denaturing gel.

Microarray Experimental Design and Analysis
-------------------------------------------

Gene expression changes were analyzed using custom human, mouse and rat cDNA microarrays as previously described \[[@B16],[@B31],[@B32]\]. Responses to CHX and TCDD co-treatment were also assayed with cDNA microarrays using a 2 × 2 factorial design (Additional file [20](#S20){ref-type="supplementary-material"}) \[[@B33]\]. Three replicates were performed with two independent labelings per sample (dye swap). In total, 42 cDNA microarrays were performed for each individual cell line. Additionally, 4 × 44 k Agilent Technologies whole-genome oligonucleotide microarrays (Santa Clara, CA), were used to profile the responses elicited by TCDD 24 hrs post-treatment according to the manufacturer\'s Two-Color Microarray-Based Gene Expression Analysis protocol Version 5.0.1, including dye swap labelings. Three replicates were performed for a total of 9 whole genome microarrays for each cell line. Microarray data quality was first assessed using a quality assurance protocol to ensure consistent high quality data throughout all studies prior to normalization and further analysis \[[@B34]\]. Microarray data were normalized using a semiparametric method \[[@B35]\], and statistically analyzed using an empirical Bayes methods \[[@B36]\]. The data were hierarchically clustered using the Euclidian distance in Cluster 3.0 \[[@B37]\] and visualized with Java Treeview \[[@B38]\]. Functional annotation clustering of Gene Ontology (GO) terms for differentially expressed genes was performed using DAVID (Database for Annotation, Visualization, and Integrated Discovery) \[[@B39]\]. Annotation clusters with an enrichment score ≥ 1.3 were considered significantly enriched. Networks of direct and indirect molecular interactions based on the whole-genome expression data were identified and visualized using the Ingenuity Pathway Analysis <http://www.ingenuity.com>.

Quantitative Real-Time PCR
--------------------------

The same total RNA samples isolated for microarray studies were used for QRTPCR as previously described \[[@B16]\]. The copy number of each unknown sample was standardized to the geometric mean of three house-keeping genes (β-actin, Gapd, Hprt or Rpl13). Official gene names and symbols, RefSeq and Entrez Gene IDs, forward and reverse primer sequences, and amplicon sizes are provided in Additional file [21](#S21){ref-type="supplementary-material"}. Data were analyzed by analysis of variance (ANOVA) followed by Tukey\'s *post hoc*test using SAS 9.1 (SAS Institute, Cary, NC). Differences between treatment groups were considered significant when *p*\< 0.05.

Computational DREs Searches
---------------------------

The proximal promoter region (10 kb upstream and 1 kb downstream of a TSS) for a RefSeq corresponding to an individual gene were computationally searched for the substitute intolerant 5\'-GC[G]{.ul}TG-3\' DRE core sequence and the position relative to the TSS were determined using the center of the 5 bp core (underlined). Each core was then extended by 7 bp upstream and downstream of the core to generate a 19 bp DRE core containing sequence, which were assigned a matrix similarity using a previously defined algorithm \[[@B18]\] and with an updated position weight matrix \[[@B17]\]. The 19 bp DRE core sequences from orthologous human, mouse and rat genes were hierarchically clustered in R <http://www.R-project.org> by measuring the Euclidean distance between pairs of sequences. DRE sequences that clustered together with a distance value ≤ 3.0 were characterized as orthologous DREs.
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###### Additional File 1

**HepG2 TCDD time course and cycloheximide cotreatment cDNA microarray data**. A table containing the expression ratios relative to the time matched vehicle control for the time course study. Ratios for the cycloheximide studies are relative to the treatment condition. P1(t)-values represent posterior probabilities of activity on a per gene and time-point basis or treatment condition using the model-based t-value.
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###### Additional File 2

**Hepa1c1c7 TCDD time course and cycloheximide cotreatment cDNA microarray data**. A table containing the expression ratios relative to the time matched vehicle control for the time course study. Ratios for the cycloheximide studies are relative to the treatment condition. P1(t)-values represent posterior probabilities of activity on a per gene and time-point basis or treatment condition using the model-based t-value.
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###### Additional File 3

**H4IIE TCDD time course and cycloheximide cotreatment cDNA microarray data**. A table containing the expression ratios relative to the time matched vehicle control for the time course study. Ratios for the cycloheximide studies are relative to the treatment condition. P1(t)-values represent posterior probabilities of activity on a per gene and time-point basis or treatment condition using the model-based t-value.

###### 

Click here for file

###### Additional File 4

**Common differentially regulated orthologs elicited by TCDD in human HepG2 and mouse Hepa1c1c7 cells identified from the cDNA microarray time course studies**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 5

**Common differentially regulated orthologs elicited by TCDD in rat H4IIE and mouse Hepa1c1c7 cells identified from the cDNA microarray time course studies**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 6

**Common differentially regulated orthologs elicited by TCDD in human HepG2 and rat H4IIE cells identified from the cDNA microarray time course studies**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 7

**Putative human primary response genes and the number of DREs in their promoters**. A table listing the putative primary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 8

**Putative mouse primary response genes and the number of DREs in their promoters**. A table listing the putative primary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 9

**Putative rat primary response genes and the number of DREs in their promoters**. A table listing the putative primary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 10

**Putative human secondary response genes and the number of DREs in their promoters**. A table listing the putative secondary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 11

**Putative mouse secondary response genes and the number of DREs in their promoters**. A table listing the putative secondary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 12

**Putative rat secondary response genes and the number of DREs in their promoters**. A table listing the putative secondary response genes identified from the cycloheximide studies and the number of 5\'-GCGTG-3\' DRE cores in the region 10 kb upstream and 1 kb downstream of a TSS.
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###### Additional File 13

**Whole-genome Agilent microarray data from HepG2 cells treated with TCDD for 24 hrs**. A table containing the expression ratio relative to the time matched vehicle control. P1(t)-values represent posterior probabilities of activity on a per gene basis using the model-based t-value.
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###### Additional File 14

**Whole-genome Agilent microarray data from Hepa1c1c7 cells treated with TCDD for 24 hrs**. A table containing the expression ratio relative to the time matched vehicle control. P1(t)-values represent posterior probabilities of activity on a per gene basis using the model-based t-value.
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###### Additional File 15

**Whole-genome Agilent microarray data from H4IIE cells treated with TCDD for 24 hrs**. A table containing the expression ratio relative to the time matched vehicle control. P1(t)-values represent posterior probabilities of activity on a per gene basis using the model-based t-value.
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###### Additional File 16

**Common differentially regulated orthologs elicited by TCDD in human HepG2 and mouse Hepa1c1c7 cells identified from the whole-genome Agilent microarrays at 24 hrs**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 17

**Common differentially regulated orthologs elicited by TCDD in rat H4IIE and mouse Hepa1c1c7 cells identified from the whole-genome Agilent microarrays at 24 hrs**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 18

**Common differentially regulated orthologs elicited by TCDD in human HepG2 and rat H4IIE cells identified from the whole-genome Agilent microarrays at 24 hrs**. A table containing the expression ratios for significantly differentially regulated orthologs (\|fold change\| \> 1.4 and P1(t) \> 0.999).
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###### Additional File 19

**Cell culture TCDD treatment and harvesting regimen**. For the time course studies, cells were treated with 10 nM TCDD or 0.1% DMSO vehicle and harvested at 1, 2, 4, 8, 12, 24, or 48 hrs post-treatment. For the cycloheximide studies cells were treated with 10 mg/ml cycloheximide 1 hr and then treated with either 10 nM TCDD or 0.1% DMSO vehicle and for an additional 4 or 12 hrs (as indicated by \*).
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###### Additional File 20

**2 × 2 Factorial microarray experimental design used for the cycloheximide expression studies**. The hybridization design used to identify putative primary and secondary gene expression responses elicited by TCDD. Each arrow represents one microarray where the arrow heads and tails refer to Cy5 and Cy3 dye labeling, respectively. Double-headed arrows indicate dye swaps (each sample labeled with Cy3 and Cy5 on different microarrays).
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###### Additional File 21

**Gene symbols and primer sequences for QRTPCR**. A list of genes and primer sequences used to verify cDNA and Agilent microarray responses.
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